News Archive

As part of the widespread media coverage of the launch of Altos Labs and the rising tide of investment into rejuvenation biotechnology, a recent article in a British daily featured an interview with SENS Research Foundation’s Science Writer Michael Rae on Altos Labs, cellular reprogramming, and its place within the SENS platform of rejuvenation biotechnologies and the push toward a future of indefinite medical maintenance of healthy, youthful life.

SRF is elated at the announcement in Longevity Technology of a fund that will distribute more than $1 billion over a ten year period specifically “to research, institutions and projects advancing healthy human longevity and extending the healthy human lifespan to more than 120 years.”

Few may remember the environment in which SRF began, in which interest in longevity research and significant extension of human life was far outside the mainstream. This financial commitment is another hard-fought victory in shifting attitudes towards fighting aging.

Buck scientists will identify and characterize senescent cells – recognized as a driver of age-related disease – in human ovaries, breast tissue and skeletal muscle. “We are thrilled that the NIH is investing in studying cellular senescence in humans…” said Campisi.